Scott Bembenek's Contact Details

Scott Bembenek's Company Details

Denovicon Therapeutics

San Diego, California, United States • 1 Employees
Research

Denovicon seamlessly integrates AI, machine learning, and molecular modeling approaches (such as quantum chemistry, molecular dynamics, and free-energy methods) into its (hybrid) computational drug discovery platform. With it, a vast amount of chemical space (~10^27 molecules) is quickly and accurately triaged, with only the most desirable analogs being identified as hits that are then ultimately transformed into clinical candidates. Currently, we are focused on targets in the DNA damage response (DDR) pathways. In particular, we are progressing first-in-class molecules forward that selectively target PARP1 and PARP2 as therapeutics for a variety of cancers, neurodegenerative conditions, and cardiovascular diseases.